Integrates state-of-the-art flow cytometry clinical trial services with leading solutions in genomics, proteomics, and molecular pathology under one roof
HUNTSVILLE, Ala., July 11, 2023/PRNewswire/ — Discovery Life Sciences (Discovery), the specialists in biospecimens and biomarkers, announces the launch of next-generation flow cytometry clinical trial services. Discovery has integrated Cytek Aurora instruments, which use full-spectrum technology to provide researchers with unprecedented flexibility, into a single facility along with its genomics, molecular pathology, and proteomics services, saving valuable time and further ensuring high quality for drug and diagnostic development.
The addition of clinical flow cytometry strengthens Discovery’s position as a leading specialty contract laboratory. Investigators will now benefit from advanced instrumentation that allows simultaneous analysis of up to 40 color combinations, significantly improving the efficiency and accuracy of their clinical trial data collection and analysis.
Discovery clients can select specific parameters that align with their research goals, enabling rapid immune monitoring and a deeper understanding of complex biological systems. They can also access a market-leading combination of technologies and expertise through a comprehensive suite of services, including multi-parameter flow cytometry, blood and tissue biological samples, genomic profiling, proteomics analysis, and molecular pathology.
“We are excited to add the capability of the newest Cytek Aurora instruments along with scientific expertise in clinical flow cytometry services to our company,” said Glenn Bilawsky, CEO of Discovery Life Sciences. “This investment furthers our commitment to provide researchers with the most advanced technology and scientific consultation to support their clinical trial needs. By combining clinical flow cytometry services in the same facility and supporting data system as well as genomics, proteomics and molecular pathology, we will further accelerate the development of life-changing therapies for our clients.”
Discovery’s clinical flow cytometry services are backed by a team of highly-skilled scientists and researchers with extensive experience in regulation, compliance, and clinical trial support. The company’s dedication to quality assurance, data security and compliance provides clients with accurate, reliable and acceptable results quickly and at any scale.
To learn more about Discovery Life Sciences’ innovative clinical flow cytometry services, visit https://www.dls.com/biomarker-services/cell-services/flow-cytometry.
About Discovery Life Sciences
Discovery Life Sciences is the company of specialist biospecimens and biomarkers, combining the world’s largest commercial biospecimen inventory and acquisition network with preeminent multiomics biomarker service laboratories, including genomic, tissue biomarker, proteomic, and protein-based services. cells to accelerate new biomarker-supported therapies and complementary diagnostic programs for cancer, infectious diseases, and other rare and complex conditions.
Through AllCells, our cell and gene therapy division, we maintain the largest recoverable donor pool to supply fresh and cryopreserved human cell materials of clinical grade and for Research Use Only (RUO) to support programs of cell and gene therapy at any stage of development and at any scale.
Driven by leading scientific expertise and innovative use of today’s technologies, Discovery’s team engages with clients to quickly overcome obstacles and deliver results to make critical research and development decisions at market-leading speed. We are Science at your Service™! For more information, visit www.dls.com.
Logo – https://mma.prnewswire.com/media/1022478/4156245/Discovery_LS_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/discovery-life-sciences-acelera-los-ensayos-clinicos-con-citometria-de-flujo-clinico-de-espectro-completo-301874466.html
